KPTI News and Press, Karyopharm Therapeutics Inc. From 06/13/22

Karyopharm Therapeutics (NASDAQ:KPTI) has disclosed a ~$3.4M share sale by director Deepika Pakianathan. Pakianathan sold 538,784 shares of the company's common stock at $6.00 - $6.64 price range. Karyopharm (KPTI) recently appeared on Truist's list of companies with less than 12 months of ca...

Bluebird Bio (BLUE), Clovis Oncology (NASDAQ:CLVS) and Chimerix (CMRX) are trading lower in the morning hours Thursday after Truist said that the three biotechs are at the risk of running out of cash within the next six months. The analysis of 118 companies developing cancer medications exclu...

Karyopharm to Participate at the Jefferies Healthcare Conference PR Newswire NEWTON, Mass. , June 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today annou...

Karyopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Meeting PR Newswire – Encouraging Initial Data Observed in Phase 1/2 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Inclu...

The U.S. Food and Drug Administration (FDA) on Thursday granted its Orphan Drug Designation for Karyopharm Therapeutics (NASDAQ:KPTI) for the company’s leading product, selinexor in myelofibrosis. Selinexor is designed to selectively bind and inhibit the nuclear export protei...

Karyopharm Therapeutics (NASDAQ:KPTI) and the European Myeloma Network (EMN), a collaboration of centers for multiple myeloma in Europe and Australia, said the first patient was dosed in the collaborative EMN29/XPORT-MM-031 study. The global phase 3 trial is evaluating an all-oral regime...

The European Myeloma Network and Karyopharm Announce Dosing of First Patient in Collaborative EMN29/XPORT-MM-031 Study PR Newswire - Phase 3 Study Evaluating an All Oral Regimen of Selinexor in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with R...

Karyopharm Therapeutics (NASDAQ:KPTI) on Friday said a European Union drug regulator committee had recommended extending the indication for the company's medicine Nexpovio for the treatment of patients with multiple myeloma, a type of white blood cell cancer. KPTI stock +4.6% t...

Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma PR Newswire ̶  European Commission Decision Anticipated within Approximately 60 Days – ...

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Karyopharm Therapeutics Inc. 2022 Q1 - Results - Earnings Call Presentation